SCNX

Scienture is a sub-$15M shell-turned-specialty-pharma that generated just $432K of revenue in FY2025 against a $41.5M net loss and a -$42.6M operating loss — an operating margin of roughly -9,868%. The 'business' is essentially two just-launched products (a hypertension drug and an opioid-overdose product) and a pre-clinical pipeline; there is no revenue base to underwrite the story. Paying 32.4x sales for a company losing ~100x its revenue is not a valuation — it's an option on a binary commercialization outcome that the filing gives no evidence is working. The five-year revenue path ($9.89M → $10.3M → $1.36M → $137K → $432K) shows a business that has been gutted, not built, as the old operations were sold or discontinued and the Scienture LLC shell (acquired July 25, 2024) was dropped in.

Liquidity is the acute problem. Operating cash flow was -$13.4M in FY2025 against only $6.66M of cash — well under a year of runway at the current burn. Funding that gap explains the 224.7% jump in shares outstanding, and the FY2025 diluted EPS of -$2.70 shows how brutally that dilution compounds per-share losses. The accumulated deficit sits at -$80.6M against $70.1M of equity, and that equity is largely non-current, intangible-flavored: only $7.92M of the $84.2M in assets is current. The clean-looking 0.20x liabilities/equity ratio is cosmetic — the risk here is not leverage, it's running out of cash and diluting holders toward zero.